Subsequently, based on the LassoCox regression analysis, we established a novel 4 PRG (CASP4, GSDMC, IL18 and NLRP2) signature to further evaluate the overall survival of PAAD patients. Here, NLRP2 is linked to pancreatic adenocarcinoma.